
The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …
Aveo Oncology and Astellas Pharma are to abandon their three-year old collaboration and licence agreement for investigational tyrosine kinase inhibitor …
Aveo will make major jobs cuts this year after news that a kidney cancer licence for its oncology drug tivozanib …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

